Latest Clinical Trials
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy ETOP IBCSG Partners Foundation NA
TERMINATED
(Sep 1, 2026)
PHASE3 To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Sep 1, 2026)
PHASE3 Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer ETOP IBCSG Partners Foundation NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Ivabradine for Heart Rate Control In Septic Shock Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Sep 1, 2026)
PHASE3 CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Roswell Park Cancer Institute NA
COMPLETED
(Sep 1, 2026)
PHASE2 Allergy and COVID-19 Vaccines Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Sep 1, 2026)
PHASE3 Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status ETOP IBCSG Partners Foundation NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Sep 1, 2026)
PHASE3 NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial Roswell Park Cancer Institute NA
RECRUITING
(Sep 1, 2026)
PHASE2 Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Roswell Park Cancer Institute NA
RECRUITING
(Sep 1, 2026)
PHASE1 Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Roswell Park Cancer Institute NA
SUSPENDED
(Sep 1, 2026)
PHASE1 A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 ETOP IBCSG Partners Foundation NA
RECRUITING
(Sep 1, 2026)
PHASE2 Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) Sparrow Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE2 Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury HealthPartners Institute NA
RECRUITING
(Sep 1, 2026)
PHASE1 Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax Timothy Pardee NA
RECRUITING
(Sep 1, 2026)
PHASE2 CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer Roswell Park Cancer Institute NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. Gustave Roussy, Cancer Campus, Grand Paris NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Topical Clobetasol Propionate for Inflammatory Hand Osteoarthritis Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Use of Bone Marrow Stem Cells (MesenCell) for the Treatment of Patients With Chronic Graft-versus-host Disease Pontifícia Universidade Católica do Paraná NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
TERMINATED
(Aug 1, 2026)
PHASE2 A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
TERMINATED
(Aug 1, 2026)
PHASE2 Clinical Studies of Gemcitabine-Oxaliplatin Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE1 Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE3 Epicutaneous Immunotherapy in Peanut Allergy in Children Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE1 Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE1 Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE1 Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE3 Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE2 Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases Roswell Park Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC ETOP IBCSG Partners Foundation NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 Gustave Roussy, Cancer Campus, Grand Paris NA
RECRUITING
(Aug 1, 2026)
PHASE3 Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Aug 1, 2026)
PHASE3 Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Roswell Park Cancer Institute NA
TERMINATED
(Aug 1, 2026)
PHASE1, PHASE2 Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Aug 1, 2026)
PHASE3 Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Roswell Park Cancer Institute NA
SUSPENDED
(Aug 1, 2026)
PHASE2 Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd Gustave Roussy, Cancer Campus, Grand Paris NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering From Gender Dysphoria Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Aug 1, 2026)
PHASE3 Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Aug 1, 2026)
PHASE2 SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Roswell Park Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE1 Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease Roswell Park Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE2 Corticosteroids Before Extubation in Pediatric Intensive Care Unit Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. Paradigm Biopharmaceuticals Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial Roswell Park Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE2 Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Roswell Park Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Aug 1, 2026)
PHASE2 Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring. HealthPartners Institute NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Enhancing Amoxicillin Pharmacokinetics and Pharmacodynamics Parameters With Probenecid in Bone and Joint Infections Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Roswell Park Cancer Institute NA
WITHDRAWN
(Jul 1, 2026)
PHASE1, PHASE2 SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Gustave Roussy, Cancer Campus, Grand Paris NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery Roswell Park Cancer Institute NA
SUSPENDED
(Jul 1, 2026)
PHASE1, PHASE2 Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Jul 1, 2026)
PHASE2 AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Jul 1, 2026)
PHASE2 Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Jul 1, 2026)
PHASE2, PHASE3 Treatment of Non-ischemic Cardiomyopathies by Intravenous Extracellular Vesicles of Cardiovascular Progenitor Cells Assistance Publique - Hôpitaux de Paris NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 FOG-001 in Locally Advanced or Metastatic Solid Tumors Parabilis Medicines, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone Sparrow Pharmaceuticals NA
COMPLETED
(Jul 1, 2026)
PHASE1 Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion NA
RECRUITING
(Jul 1, 2026)
PHASE3 Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Roswell Park Cancer Institute NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation Hematology department of the 920th hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome Molecular Partners AG NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer Roswell Park Cancer Institute NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Glutide for Ending Methamphetamine San Francisco Department of Public Health NA
RECRUITING
(Jun 1, 2026)
PHASE2 Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD NA
RECRUITING
(Jun 1, 2026)
PHASE3 Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID ParagonClinicals Inc. NA
RECRUITING
(Jun 1, 2026)
PHASE2 Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. Hematology department of the 920th hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy CMC Ambroise Paré NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants Albert Park NA
TERMINATED
(May 1, 2026)
PHASE2 Effect of Naloxegol on Postoperative Ileus in Patients Undergoing Cardiac Surgery CMC Ambroise Paré NA
COMPLETED
(May 1, 2026)
PHASE3 Baricitinib in Patients With Relapsing or naïve Dermatomyositis Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(May 1, 2026)
PHASE3 Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder Parnassia Addiction Research Centre NA
RECRUITING
(May 1, 2026)
PHASE2 Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma Roswell Park Cancer Institute NA
WITHDRAWN
(May 1, 2026)
PHASE1 Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(May 1, 2026)
PHASE3 KetAmine and Recovery After Mechanical VentilAtion ( KARMA ) Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Adjuvant Trial in Pancreatic Neuroendocrine Tumors Gustave Roussy, Cancer Campus, Grand Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Electrophysiological Analysis of Gamma-Hydroxybutyrate-induced Sleep in Intensive Care Patients Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia (FOVOCIP) Fundación para la Investigación Biosanitaria del Principado de Asturias NA
COMPLETED
(May 1, 2026)
PHASE3 KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Effect of Bosentan in Scleroderma Renal Crisis Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Apr 1, 2026)
PHASE2 Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Roswell Park Cancer Institute NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy Roswell Park Cancer Institute NA
COMPLETED
(Apr 1, 2026)
PHASE2 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma ETOP IBCSG Partners Foundation NA
COMPLETED
(Apr 1, 2026)
PHASE3 Dexmedetomidine Intra Venous Arthroplasty CMC Ambroise Paré NA
COMPLETED
(Apr 1, 2026)
PHASE3 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Apr 1, 2026)
PHASE3 Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation Assistance Publique - Hôpitaux de Paris NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma ETOP IBCSG Partners Foundation NA
COMPLETED
(Apr 1, 2026)
PHASE2 Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Roswell Park Cancer Institute NA
RECRUITING
(Apr 1, 2026)
PHASE1 Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery CMC Ambroise Paré NA
COMPLETED
(Apr 1, 2026)
PHASE3 ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial. Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Apr 1, 2026)
PHASE3 Opioid Free Anesthesia in Total Hip Arthroplasty CMC Ambroise Paré NA
COMPLETED
(Apr 1, 2026)
PHASE3 Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Apr 1, 2026)
PHASE1 Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers Partner Therapeutics, Inc. NA
TERMINATED
(Apr 1, 2026)
PHASE2 Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) Assistance Publique - Hôpitaux de Paris NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis Assistance Publique - Hôpitaux de Paris NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Apr 1, 2026)
PHASE2 Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Apr 1, 2026)
PHASE3 Bosentan in the Treatment of Giant Cell Arteritis Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Phase 1 Study of PVT401 in Healthy Subjects Parvus Therapeutics, Inc. NA
RECRUITING
(Apr 1, 2026)
PHASE1 Efficacy of Cannabidiol in the Management of Self-injuries in Children and Adolescents With Severe Neurodevelopmental Disorders. Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Mar 1, 2026)
PHASE2 Treatment of Familiar Lymphohistiocytosis Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Treatment Tapering in JIA With Inactive Disease Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Mar 1, 2026)
PHASE3 Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma Gustave Roussy, Cancer Campus, Grand Paris NA
TERMINATED
(Mar 1, 2026)
PHASE1 Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Mar 1, 2026)
PHASE2 Synbiotic Compound to Reduce Symptoms of Schizophrenia Sheppard Pratt Health System NA
RECRUITING
(Mar 1, 2026)
PHASE2 Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Mar 1, 2026)
PHASE3 APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Roswell Park Cancer Institute NA
RECRUITING
(Mar 1, 2026)
PHASE2 PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Mar 1, 2026)
PHASE3 Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Mar 1, 2026)
PHASE2 Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Mar 1, 2026)
PHASE2 Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer Assistance Publique - Hôpitaux de Paris NA
WITHDRAWN
(Mar 1, 2026)
PHASE2 Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI) Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Mar 1, 2026)
PHASE2 Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Mar 1, 2026)
PHASE2 Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease Assistance Publique - Hôpitaux de Paris NA
RECRUITING
(Mar 1, 2026)
PHASE2 Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Bioadhesive Film of Acmella Oleracea (Jambu) in the Reduction of Post-bleaching Dental Sensitivity Caused by Bleaching With 35% Hydrogen Peroxide. Universidade Federal do Para NA
COMPLETED
(Mar 1, 2026)
PHASE3 Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis Assistance Publique - Hôpitaux de Paris NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE3 Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury Swiss Paraplegic Research, Nottwil NA
WITHDRAWN
(Jan, 2019)
PHASE4 Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban Assistance Publique - Hôpitaux de Paris NA
COMPLETED
(Mar, 2011)
PHASE2, PHASE3 Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation Assistance Publique - Hôpitaux de Paris
Agence de La Biomédecine
COMPLETED
(Jul, 2009)
PHASE2 
